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Detect Necrotic
Core–Rich Plaque?I read with great interest the paper by Pu et al. (1)
in the Journal and congratulate the investigators on
an excellent study, which contributes greatly to
our current knowledge of intravascular ultrasound
(IVUS). It is generally accepted that grayscale IVUS is
limited to the detection of lipid-rich necrotic core
lesions, and there is no speciﬁc grayscale ultrasonic
signature associated with necrotic core. However, Pu
et al.’s (1) IVUS histological validation study of 2,294
human coronary autopsy specimens from victims of
cardiovascular death showed that echo attenuation,
in particular that with superﬁcial location, is a reliable
grayscale IVUS signature for high-risk plaque con-
taining a large necrotic core. This novel ﬁnding is
interesting and has clinical relevance because the
assessment of high-risk plaque using conventional
grayscale IVUS, because of its wide availability, has
broad interest for cardiologists. However, 2 items
warrant further clariﬁcation for readers to use this
novel echo-attenuated signature in ischemic event
risk stratiﬁcation.
R
E
TFirst, although “echo-attenuated plaque” was
identiﬁed by the absence of ultrasound signal behind
plaque that was either hypoechoic or isoechoic to
reference adventitia but without bright calcium in
their study (1), it had previously been identiﬁed by
ultrasound attenuation behind either hypoechoic
plaque or hypoechoic or mixed plaque (2). Therefore,
the deﬁnition of echo-attenuated plaque would
have to be standardized for clinical practice
implementation.
Second, ﬁndings on the location of lipid/necrotic
core in echo-attenuated plaque in this in vitro study
(1) appear inconsistent with those in an in vivo study
by the same research team using IVUS–virtual his-
tology in patients with acute coronary syndromes in
whom necrotic core appeared at the echogenic “cap”
of the plaque but not at the site of echo attenuation
(3). Because ﬁbrous cap thickness and necrotic core
location are critical to plaque vulnerability, it might
be of value if Pu et al. provided quantitative infor-
mation on ﬁbrous cap thickness of echo-attenuated
plaque and interpreted the disparity between their
in vitro and in vivo study results.
In addition, given that echo-attenuated plaque has
not been described in the existing IVUS guidelines
(4,5), I believe that the current qualitative plaque
classiﬁcation scheme by IVUS grayscale image char-
acteristics should be updated on the basis of the
novel ﬁndings by Pu et al. (1) on echo-attenuated
plaque.
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Necrotic Core–Rich Plaque?We appreciate the interest by Dr. Falk in our paper (1)
and his insightful comments, which especially focus
on our ﬁndings regarding echo-attenuated plaque. In
comparison to the gold standard of histopathology in
2,294 human coronary autopsy specimens, we found
that echo-attenuated signature, in particular that
with superﬁcial location, indicated a high-risk plaque
containing a large necrotic core (NC).
We agree with Dr. Falk’s comment that the deﬁni-
tion of “echo-attenuated plaque” should be stan-
dardized for clinical practice implementation. On
the basis of our study, we recommend that the gray-
scale intravascular ultrasound (IVUS) echo-attenuated
signature be deﬁned as the absence of ultrasound
signal behind plaque that was either hypoechoic ortion of Histologic Lipid/NC in Relation to Echo Attenuation
ess of “echogenic cap” of the echo-attenuated plaque on the intra-
(IVUS) imaging was different from that of the histologic ﬁbrous cap
crotic core (NC) on the pathological imaging.isoechoic to reference adventitia, but without bright
calcium. By deﬁnition, echo-attenuated plaque excludes
“attenuation (or, more correctly, shadowing) behind
hyperechoic calcium.” Our proposal would certainly be
the most speciﬁc, although a deﬁnition that includes
mixed plaque might be more sensitive.
Furthermore, we propose to deﬁne the location of
attenuation as superﬁcial (leading edge of attenuation
closer to the lumen than to the adventitia) or deep
(leading edge of attenuation closer to the adventitia
than to the lumen). As demonstrated in our paper (1),
the location of attenuation was an important charac-
teristic related to plaque biologic instability. Dr. Falk
expresses concern about the “different” ﬁndings on
the echo-attenuated plaques in this in vitro study
using histopathology in patients at necropsy (1) versus
ﬁndings in our recent in vivo study using virtual his-
tology-IVUS in patients with acute coronary syn-
dromes (2). In particular, he is concerned with the
location of lipid/NC in relation to echo attenuation.
First, because the thickness of the “echogenic cap” of
the echo-attenuated plaque was different from that of
the histologic ﬁbrous cap covering the lipid/NC and
because trailing-edge measurements by ultrasound
might be unreliable, we did not present data regarding
the “cap” thickness in the setting of echo attenuation
in the present study. Second, it should be noted that
in our IVUS histological validation study, the leading
edge of the histologic lipid/NC that produced attenu-
ation was always in front of the leading edge of
attenuation on IVUS. In other words, the lipid/NC
produces both the “echogenic cap” that is superﬁcial
to the area of attenuation as well as the attenuation
itself; in fact, as shown in Figure 1, the 2 are interre-
lated. This is analogous to calcium that produces both
a hyperechoic acoustic signature as well as deeper
shadowing. Third, current grayscale IVUS technology
does not have the ability to resolve a ﬁbrous cap
thickness <65 mm, the commonly accepted criterion
for a thin-cap ﬁbroatheroma. Finally, the more ad-
vanced the atherosclerotic plaque, the more complex
and heterogeneous the plaque components that
contributed to attenuation of ultrasound signal (i.e.,
the closer to the leading edge of the lipid/NC).
We do concur with Dr. Falk that the current quali-
tative plaque classiﬁcation scheme by IVUS grayscale
image characteristics, which do not correlate well with
histological plaque composition, should be updated.
The cited papers are both more than 10 years old, and
as pointed out by Dr. Falk, echo-attenuated signature
is a novel IVUS signature that is not described in the
existing IVUS guidelines or consensus documents. It
would be especially valuable if such an update were
done using outcomes data as the end point.
